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Uroporphyrin I (URO I) accumulation has been reported in 
the bone marrow of rats exposed to lead, suggesting a sensitivity 
of uroporphyrinogen III cosynthase (COSYN) to this heavy 
metal. Furthermore, it has been reported that a polyglutamated 
folate derivative may serve as a coenzyme for the catalytic action 
of hepatic uroporphyrinogen III cosynthase. These findings 
raised the question of whether depletion of polyglutamated folate 
could enhance the susceptibility of bone marrow COSYN to 
lead and potentially interfere with the formation of heme. Nitrous 
oxide, an anesthetic agent capable of causing bone marrow tet- 
rahydrofolate deficiency, depressed total bone marrow polyglu- 
tamated folate content by 42% with significant reductions in all 
three chain lengths (5-7) identified in the bone marrow during 
an exposure period of 7 days at 4 hr/day. Lead acetate (15 mgl 
kg) administered by ip injection at Days 0 and 2 during a 7-day 
exposure to nitrous oxide resulted in an 84% increase of bone 
marrow URO I content, which was markedly higher than the 
increases of 22 and 38% seen with sole administration of lead 
or nitrous oxide, respectively. The combination of agents also 
produced a 48% rise in COPRO I, a 39 and 43% decrease in 
COPRO III and protoporphyrin, respectively, and a 42% decline 
in the activity of microsomal 7-ethoxycoumarin O-deethylase, 
which is hemoprotein, cytochrome P-450 mediated. Heme ox- 
ygenase activity was not altered by nitrous oxide, lead, or their 
combination. These results suggest hat bone marrow folate de- 
ficiency may render COSYN more sensitive to lead as charac- 
terized by increased uroporphyrin I and coproporphyrin I isomer 
content, decreased coproporphyrin III and protoporphyrin con- 
tent, and depressed microsomal hemoprotein, cytochrome P- 
450-mediated drug-metabolizing capability. o 1992 Academic press, IOC. 
There is widespread exposure to lead in our environment. 
Lead intoxication is known to cause anemia, and the bio- 
synthesis of heme is inhibited by this heavy metal. However, 
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most information on lead-impaired heme formation has been 
performed with the erythrocyte which transports oxygen but 
does not have the enzymatic capability to synthesize 
heme. 
The third step of heme biosynthesis is believed to be me- 
diated by the concerted action of two enzymes in a two-step 
reaction. The first step is catalyzed by uroporphyrinogen 
(UROGEN) I synthase (URO-S) (EC 4.3.1.8), which converts 
four molecules of the pyrrole porphobilinogen into the un- 
stable intermediate hydroxymethylbilane. The low activity 
of this enzymatic reaction in tissue indicates that this step 
may become potentially rate-limiting for the synthesis of 
heme. Hydroxymethylbilane, serving as the substrate for 
uroporphyrinogen III cosynthase (COSYN) (EC 4.2.1.75), is 
then converted into the biologically active heme precursor 
uroporphyrinogen III. Without COSYN, hydroxymethyl- 
bilane spontaneously cyclizes into uroporphyrinogen I, which 
is useless as a substrate for COSYN and thus cannot be uti- 
lized in the synthesis of heme. Uroporphyrinogen I is able 
to serve as a substrate for the next enzyme in the heme bio- 
synthetic pathway, uroporphyrinogen decarboxylase, which 
forms coproporphyrinogen I. These uro- and copropor- 
phyrinogens are rapidly oxidized to form uroporphyrin 
(URO) and coproporphyrin (COPRO). Therefore, COSYN 
can be considered a “specifier protein” that ensures the syn- 
thesis of uroporphyrinogen III from hydroxymethylbilane 
with the combined catalytic action of URO-S (Tait, 
1978; Burton et al., 1979; Jordan et al., 1979). 
The rare disease of congenital erythropoietic porphyria is 
believed to be due to an inherited enzymatic defect in uro- 
porphyrinogen III cosynthase, causing excretion of excess 
URO I and COPRO I in the urine (Deybach et al., 198 1). 
In addition, URO I accumulation has also been reported in 
the bone marrow of lead poisoned rats (Christenson et al., 
1985) and rabbits (Schmid et al., 1952). These findings, to- 
gether with a study by Kohashi et al. (1984) indicating that 
COSYN may require a reduced pteroylpolyglutamate co- 
enzyme in order to facilitate UROGEN III biosynthesis, 
prompted us to investigate the effect of folate deficiency in 
regulating the toxic response of COSYN to lead in the bone 
marrow of the rat. 
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MATERIALS AND METHODS 
Chemicals. Folic acid, gelatin, reagent-grade Trizma Base, Coomassie 
brilliant blue G, bovine serum albumin (type V), NADPH, NADH (grade 
III), 7-etboxycoumarin, umbelliferone (grade II), hemin (type III), isocitric 
acid, isocitric dehydrogenase, and heparin were obtained from Sigma 
Chemical Co. (St. Louis, MO). Porphobilinogen, protoporphyrin, uropor- 
phyrin I octamethyl ester, uroporphyrin III octamethyl ester, coproporphytin 
I tetramethyl ester, and coproporphyrin III tetramethyl ester were purchased 
from Porphyrin Products (Logan, UT). HPLC-grade acetonitrile and water 
were obtained from MCB Manufacturing Chemists, Inc. (Cincinnati, OH), 
and HPLC-grade glacial acetic acid was purchased from J. T. Baker (Phil- 
lipsburg, NJ). Bio-Gel P2 (200-400 mesh) was obtained from Bio-Rad Lab- 
oratories (Richmond, CA). Pteroylpentaglutamate, pteroylhexaglutamate, 
and pteroylheptaglutamate standards were generous gifts from Dr. E. L. R. 
Stokstad at the University of California, Berkeley. All other laboratory re- 
agents were of analytical grade and were purchased from Mallinckrodt 
Chemical Works (St. Louis, MO). 
Animals. Adult, male Sprague-Dawley rats (Sasco, Omaha, NE; 180- 
200 g) were housed in hanging cages in groups of three and were exposed 
to a 12-hr light/dark cycle (6:00 AM lights on; 6:00 PM lights off). Food 
(Purina Laboratory Rodent Chow, Ralston-Purina Co., St. Louis, MO) and 
water were provided ad libitum. Lead acetate, dissolved in 0.9% NaCl, was 
administered by ip injection at Days 0 and 2 followed by decapitation at 7 
days. Controls received equivalent volumes of 0.9% NaCl (4 ml/kg). A de- 
ficiency of tetrahydrofolate in bone marrow was produced by exposure of 
rats to nitrous oxide, an inhibitor of methionine synthetase, which catalyzes 
the formation of tetrahydrofolate and methionine from methyltetrahydro- 
folate and homocysteine. For nitrous oxide experiments, rats were placed 
in a 30-liter specially constructed metabolic chamber through which flowed 
NzO/Oz (1: 1) at 4 hr/day (9:00 AM-1:OO PM) for 7 days. The total flow of 
gas was 8 liters/min. Controls were exposed to room air. 
Tissueporphyrin analysis. Porphyrins were isolated from the bone mar- 
row of the femur as described by Reddy et al. (1987). Uro- and copropor- 
phyrin isomers were separated and quantitated by reverse-phase HPLC ac- 
cording to the methods of Rideout et al. (1983) and Wright et al. (1983), 
respectively. Protoporphyrin levels were also assessed by reverse-phase HPLC 
as described by Lim et al. ( 1984). All analyses were performed on a Waters 
Associates liquid chromatograph (Model 6000A solvent delivery system and 
Rheodyne 7 125 injector) interfaced with a Schoeffel Model FS 970 fluorom- 
eter equipped with either a Cl8 bonded column (spherical 5 mm, 4.5 mm 
inner diameter X 25 cm) from IBM Instruments, Inc. (Danbury, CT), for 
uro- and coproporphyrin determinations, or a CI bonded column (spherical, 
5 mm, 4.5 mm inner diameter X 15 cm) from Shandon Instruments, Inc., 
(UK) for protoporphyrin analysis. A Cl8 bonded-guard column (spherical, 
10 mm; 4.6 mm inner diameter; X3 cm) from Brownlee Labs (Santa Clara, 
CA) was located between the pump and the analytical column. 
Polyglutamated folate analysis. Bone marrow polyglutamated folate 
levels were determined utilizing the method of Shane (1982). All analyses 
were performed on a Perkin-Elmer Series 3 liquid chromatograph, utilizing 
a Perkin-Elmer Model 204A fluorescence spectrophotometer with excitation 
and emission wave lengths of 3 10 and 360 nm, respectively, and a Whatman 
Partisil 10 SAX analytical column (4.5 mm X 25 cm). A precolumn (4.5 
mm X 3 cm) was placed before the injection port, and a guard column (4.6 
mm X 3 cm) from Brownlee Labs containing a strong anionic exchanger 
was attached between the injection port and the analytical column. 
Microsomal heme oxygeaase assay. Bone marrow microsomal heme 
oxygenase activity was determined by the method of Ibrahim and Levere 
(1980). Product formation was found to be linear for 20 min with up to 1.0 
mg of protein. 
Assay of boae marrow micnxomal drag metabolism. 7-Ethoxycoumarin 
O-deethylase activity was determined by the fluorometric assay method of 
Greenlee and Poland ( 1978), using the method of Dresner et al. ( 198 l), in 
order to prepare bone marrow microsomes. Product formation was found 
to be linear for 15 min with up to 0.5 mg of protein. 
Protein Protein concentrations were determined by the method of 
Bradford (1976) using bovine serum albumin as the standard. 
Statistical aaalysis. Data were analyzed by a one-way analysis of variance 
using Tukey’s t test or by Student’s t test. A p value less than 0.05 was 
required for significance of difference between means. 
RESULTS 
Efect of lead on uroporphyrin I andprotoporphyrin content 
in rat bone marrow. Preliminary findings from this labo- 
ratory (Christenson et al., 1985) have indicated that uro- 
porphyrin I accumulates in the bone marrow of lead poisoned 
rats. These findings would suggest a sensitivity of COSYN 
to lead. However, it has also been postulated that lead-me- 
diated inhibition of ferrochelatase (EC 4.99.1. I), the last en- 
zyme of the pathway, could account for uroporphyrin ac- 
cumulation by causing a backup of porphyrin intermediates 
(Sassa et al., 1975). Therefore, to assess the specificity of the 
porphyrin response to lead in the bone marrow, a dose- 
response study was conducted comparing changes in pro- 
toporphyrin, the substrate of ferrochelatase, to changes in 
uroporphyrin I levels (Fig. 1). At a dose of 30 mg/kg lead 
acetate, both URO I and protoporphyrin were increased. A 
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FIG. 1. The effect of lead on URO I and protoporphyrin content in rat 
bone marrow. Lead acetate was administered ip at Days 0 and 2 followed 
by euthanasia at Day 7. Marrow was assayed for URO I and protoporphyrin 
as described under Materials and Methods. Each bar represents the mean 
+ SE for six rats. An asterisk denotes a significant difference (p < 0.05) 
between lead-treated and control rats. The mean control values for uropor- 
phyrin I and protoporphyrin were 82.6 and 348.3 pmoI/g tissue, respectively. 
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porphyrin levels remained unchanged. Neither URO I nor 
protoporphyrin was increased at 5 mg/kg. Therefore, the 
data suggest that COSYN may be subject to inhibition by 
lead, as characterized by URO I accumulation, and that the 
effect can occur at a dose that does not cause protoporphyrin 
accumulation, suggesting that URO I accumulates as a result 
of impaired COSYN. 
E#ect of lead, nitrous oxide, and their combination on 
uroporphyrin and polyglutamated folate content in rat bone 
marrow. The report of a polyglutamated folate moiety, 
functioning as a possible coenzyme to COSYN (Kohashi et 
al., 1984) and the observation that URO I accumulation, a 
condition indicative of COSYN inhibition, occurs in the 
bone marrow of lead poisoned experimental rats (Christen- 
son et al., 1985) and rabbits (Schmid et al., 1952) raised the 
question as to whether the toxicity of lead toward COSYN 
might be modulated by the folate status of the tissue. To 
examine this question, rats were exposed to nitrous oxide at 
4 hr/day for 7 days. Nitrous oxide is an anesthetic agent 
known to reduce tissue polyglutamated tetrahydrofolate 
content (Perry et al., 1979; Scott et al., 1980). As shown in 
Table 1, bone marrow COSYN activity decreased over a 7- 
day nitrous oxide exposure period. Table 1 also indicates 
that as the absolute activity of COSYN decreased, the per- 
centage of uroporphyrinogen formed as isomer I increased. 
Groups of nitrous oxide-exposed rats were also given lead 
acetate at its apparent threshold for impairment of COSYN 
(15 mg/kg at Days 0 and 2 for 7 days). As shown in Fig. 2, 
a 72% increase in bone marrow uroporphyrin was observed 
in nitrous oxide-treated rats given lead acetate, which re- 
flected an 84% increase in URO I content. This response 
was correlated to a 42% depression of total polyglutamated 
folate with significant reductions in all three chain lengths 
(Table 2) identified in the bone marrow. The simultaneous 
presence of lead had no effect on nitrous oxide-mediated 
reductions of polyglutamated folate. Lead acetate exposure 
alone failed to produce a significant increase of URO I in 
bone marrow or to alter polyglutamated folate content. 
Eflect of lead, nitrous oxide, and their combination on 
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FIG. 2. The effect of lead, nitrous oxide, and their combination on 
uroporphyrin content in rat bone marrow. Lead acetate alone (15 mg/kg) 
was administered ip at Days 0 and 2 followed by euthanasia at Day 7. Nitrous 
oxide/oxygen (1: 1) was administered 4 hr/day for 7 days. For combined 
administration, lead acetate was injected at Days 0 and 2 during the 7&y 
exposure to nitrous oxide at 4 hr/day. Following euthanasia, bone marrow 
was assayed for uroporphyrin as described under Materials and Methods. 
Each bar represents the mean + SE for three determinations. a, significant 
difference (p < 0.05) from control; b, significant difference (p < 0.05) from 
nitrous oxide; c, significant difference (p < 0.05) from lead. 
isomeric forms (types I and III) of uroporphyrinogen, the 
initial tetrapyrrole of heme biosynthesis, are normally syn- 
thesized. However, only the more abundant type III form 
can be incorporated into heme. Consequently, a marked in- 
crease in uroporphyrinogen I rather than isomer III concen- 
tration could have a significant effect on heme biosynthesis 
if the change could be translated through the pathway from 
the site of action. To test this possibility, the levels of copro- 
and protoporphyrin were also determined in the bone mar- 
row following treatment of rats with lead, nitrous oxide, or 
TABLE 1 






Uroporphyrinogen I Uroporphyrinogen III 
synthax activity cosynthase activity 
(nmol URO/mg protein/hr) (nmol URO III/mg protein/hr) 
2.94 k 0.75 25.0 + 2.3 
2.73 + 0.85 21.7 + 2.5 
2.52 k 0.77 16.2 rt 1.9’ 
URO III URO I 
(%) (%) 
79.3 * 7.0 20.7 + 5.0 
72.1 + 6.5 27.9 + 4.3 
59.6 2 6.0 40.4 _t 4.7 
’ Rats were exposed to NzO/O, (1: 1) at a rate of 4 hr/day with controls receiving room air. Animals were then euthanized at 4 or 7 days and their bone 
marrow assayed as described under Materials and Methods. Values are the averages of three experiments and are expressed as the means + SEM. 
‘p i 0.05 when compared to respective control value. 
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TABLE 2 
Effect of Lead, Nitrous Oxide, and Their Combination on 
Polyglutamated Folate Content in Rat Bone Marrow” 
Control 




5 0.28 f  0.03 
6 0.21 t 0.02 
I 0.05 + 0.01 






0.32 ?I 0.02 
0.24 + 0.03 
0.06 k 0.01 






0.13 f  0.02< 
0.10 f  o.04c 
0.02 f  0.01’ 






0.14 f  0.03’ 
0.15 f  0.02’ 
0.03 f  0.01’ 
0.32 + 0.02’ 
n Lead acetate ( 15 mg/kg) was administered ip at Days 0 and 2 followed 
by euthanasia at Day 7. Nitrous oxide/oxygen (1: 1) was administered over 
7 days at 4 hr/day (9:00 AM- 1:OO PM). For combined administration, lead 
acetate was injected at Days 0 and 2 during a 7-day exposure to nitrous 
oxide at 4 hr/day. Following euthanasia, bone marrow was assayed for poly- 
glutamated folate as described under Materials and Methods. Values represent 
the means + SEM for three rats. 
b None detected. 
’ Denotes a significant difference (p < 0.05) from control rats. 
their combination. As depicted in Fig. 3, the combination 
of lead and nitrous oxide caused a 48% increase in COPRO 
I content that was accompanied by a 39% decrease in CO- 
PRO III. A 43% decrease in protoporphyrin, the last inter- 
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FIG. 3. The effect of lead, nitrous oxide, and their combination on 
coproporphyrin in rat bone marrow. Experimental conditions were identical 
to those described in the legend to Fig. 2. Each bar represents the mean f  
SE for three determinations. a, significant difference (p < 0.05) from control; 
b, significant difference (p < 0.05) from nitrous oxide; c, significant difference 
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FIG. 4. The effect of lead, nitrous oxide, and their combination on 
protoporphyrin content in rat bone marrow. Experimental conditions were 
identical to those described in the legend to Fig. 2. Each bar represents the 
mean + SE for three determinations. a, significant difference (p < 0.05) from 
control; b, significant difference (p i 0.05) from nitrous oxide; c, significant 
difference (p < 0.05) from lead. 
mediate of heme biosynthesis, was observed (Fig. 4) in the 
bone marrow of rats exposed to lead and nitrous oxide. All 
changes were greater than those observed with administration 
of either lead or nitrous oxide alone, suggesting that the al- 
terations in porphyrin content are initiated with uropor- 
phyrinogen synthesis and were enhanced by exposure to ni- 
trous oxide. 
Effect of lead, nitrous oxide, and their combination on 
bone marrow microsomal drug metabolism. The obser- 
vation that the combined action of lead and nitrous oxide 
results in a significant, potentiated accumulation of URO I 
and COPRO I, and a marked depression of protoporphyrin 
levels suggests that microsomal heme content may also be 
depressed. To test this possibility, hemoprotein, microsomal 
cytochrome P-450-mediated drug metabolism was deter- 
mined by measuring the O-deethylation of 7-ethoxycou- 
marin to 7-hydroxycoumarin. As depicted in Fig. 5,7-ethoxy- 
coumarin O-deethylase activity was unaffected by treatment 
with lead but was decreased by 26% following nitrous oxide 
exposure. Coadministration of lead during nitrous oxide ex- 
posure resulted in a 42% decrease in enzymatic activity. 
Eflect of lead, nitrous oxide, and their combination on 
microsomal heme oxygenase activity. The observed reduc- 
tion in 7-ethoxycoumarin O-deethylase activity produced by 
coadministration of lead and nitrous oxide could also be the 
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FIG. 5. The effect of lead, nitrous oxide, and their combination on bone 
marrow microsomal drug metabolism. Experimental conditions were iden- 
tical to those described in the legend to Fig. 2. Each bar represents the mean 
+ SE for three determinations. a, significant difference (p < 0.05) from 
control; b, significant difference (p < 0.05) from nitrous oxide; c, significant 
difference (p < 0.05) from lead. 
result of an increase in the rate of heme catabolism. Micro- 
somal heme oxygenase, the first and rate-limiting enzymatic 
step in the breakdown of heme, was assayed to test this pos- 
sibility. Heme oxygenase activity was unaffected by the pres- 
ence of lead, nitrous oxide, or their combination (Fig. 6). 
Therefore, it is unlikely that accelerated heme catabolism is 
responsible for the observed depression in microsomal drug 
metabolizing capability. 
DISCUSSION 
These studies indicate that the response of bone marrow 
COSYN to lead exposure can be modified as a function of 
the folate status of the tissue. Utilizing URO I tissue accu- 
mulation as an index to COSYN impairment, the dose-re- 
sponse experiment conducted indicates the susceptibility of 
COSYN to lead. Moreover, it suggests that at low doses of 
lead URO I buildup appears to begin prior to the protopor- 
phyrin accumulation that is indicative of lead-mediated in- 
hibition of ferrochelatase. This would suggest that COSYN 
may be more sensitive to lead toxicity than ferrochelatase, 
as evidenced .by the earlier isomeric change in uroporphyrin 
I composition, which reflects the toxic response of COSYN 
to lead. However, at higher levels of lead exposure, uropor- 
phyrin accumulation could result from a combination of 
intermediate backup from inhibition of ferrochelatase (Sassa 
et al., 1975) in addition to URO I accumulation from in- 
hibition of COSYN. 
An enhanced accumulation of URO I in bone marrow in 
rats treated with lead and exposed to nitrous oxide was ob- 
served during tetrahydrofolate deficiency. Furthermore, the 
effect was accompanied by increased accumulation of CO- 
PRO I, decreased levels of COPRO III and protoporphyrin, 
and decreased activity of microsomal hemoprotein, cyto- 
chrome P-450 drug-metabolizing capability, suggesting a di- 
minished microsomal heme content as a consequence of im- 
paired uroporphyrinogen and heme formation. 
It is unlikely that lead at the dose utilized acted to inhibit 
COSYN activity through modification of folate metabolism 
since the combination of agents failed to enhance the 
depression of bone marrow polyglutamated folate (Table 2). 
Thus, it is more likely that the potentiated effect on URO I 
observed is a consequence of the direct action of lead on a 
folate-dependent COSYN enzyme that is rendered more ac- 
cessible to inhibition in the folate-deficient state. Such a pos- 
sibility is consistent with a report by Piper and van Lier 
( 1977) which indicated that pteroylpolyglutamates were ca- 
pable of protecting against inhibition of rat hepatic URO-S 
by lead and that a one-carbon transfer may be involved in 
hydroxymethylbilane rearrangement to UROGEN III in the 
presence ofCOSYN (Battersby et al., 1978, 1979, and 1980), 
implying that diminished levels of polyglutamated folate 
could induce susceptibility to lead toxicity. 
NONTREATED CONIROL 
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FIG. 6. The effect oflead, nitrous oxide, and their combination on bone 
marrow microsomal heme oxygenase activity. Experimental conditions were. 
identical to those described in the legend to Fig. 2. Each bar represents the 
mean + SE for three determinations. 
PTERIDINE REGULATION 
In conclusion, the data herein indicate that a folate deriv- 
ative may play a central role in uroporphyrinogen III syn- 
thesis and the formation of heme by regulating the response 
of COSYN to environmental toxins such as lead. These find- 
ings are important with respect to the prevalence of folic 
acid deficiency in the United States together with the major 
problem that lead poisoning represents among nutritionally 
deficient members of society. 
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